Q32 Bio Inc. 8-K

What Happened Q32 Bio Inc. (QTTB) filed a Form 8-K on April 24, 2026 disclosing that it has filed a prospectus supplement to offer and sell, at its discretion, up to $75,000,000 of common stock under its existing Controlled Equity OfferingSM Sales Agreement with Cantor Fitzgerald & Co. The company previously entered into the Sales Agreement on March 27, 2026 and had a prior prospectus supplement for up to $14,200,000, which has been fully sold. The Additional Shares will be offered under Q32 Bio’s shelf registration on Form S-3 (File No. 333-286491), declared effective April 21, 2025. Goodwin Procter LLP provided a legal opinion and consent related to the offering (included as Exhibit 5.1).

Key Details

• Prior ATM prospectus supplement (filed March 27, 2026) was fully used: $14,200,000 sold.
• New prospectus supplement filed April 24, 2026 to offer up to $75,000,000 of common stock.
• Sales Agent: Cantor Fitzgerald & Co.; offering will be made from time to time at the company’s sole discretion.
• Offering to be made under the company’s Form S-3 shelf (file no. 333-286491); Goodwin Procter LLP legal opinion attached (Exhibit 5.1).

Why It Matters This filing gives Q32 Bio flexibility to raise capital quickly by selling shares into the market as needed. For current shareholders, future sales under this program could dilute existing ownership if the company issues shares. The 8-K is informational and not an offer to sell; any actual placement of shares will occur only if and when the company elects to sell under the prospectus supplement.